Skip to: Content
Skip to: Site Navigation
Skip to: Search

July 25, 2008 6:17:36 PM CDT

Learn about Newser Points »

Stories related to: GlaxoSmithKline

Stories

16 Stories

  • April 2008

    • Serious Side Effects Linked to Avandia, Fosamax

      newser  |  Reuters  |  Apr 29, 08 2:57 AM CDT

      Serious Side Effects Linked to Avandia, Fosamax

      Two new studies have linked the popular prescription drugs Fosamax and Avandia to serious side effects, Reuters reports. Fosamax, prescribed for osteoporosis, has been tied to a type of abnormal heartbeat that can cause dizziness and fatigue. Another study links Avandia, used to treat diabetes, to a double or even triple risk of broken limbs after long-term use. More »

      Tags

      diabetes  • Merck  • GlaxoSmithKline  • Avandia  • osteoporosis  • Food and Drug Administration  • Fosamax

  • February 2008
  • January 2008

    • Beefed-Up R&D Slows Drug Approval

      newser  |  Bloomberg  |  Jan 8, 08 5:45 PM CST

      Beefed-Up R&D Slows Drug Approval

      The FDA approved only 19 new drugs in 2007, the lowest total in 24 years. Bloomberg takes a look at the reasons. Some drug companies accuse the FDA of setting the bar higher for drug approvals, a charge the agency denies. Many, however, say the issue lies with big pharma devoting more attention to developing existing products than to creating new drugs. More »

      Tags

      FDA  • GlaxoSmithKline  • drug safety  • Novartis AG

  • December 2007
  • November 2007

    • Tamiflu Will Carry Stronger Warning Labels

      newser  |  Associated Press  |  Nov 28, 07 4:51 PM CST

      Tamiflu Will Carry Stronger Warning Labels

      The maker of flu drug Tamiflu said today it will accept recommendations by a government panel that it revise printed warnings about the medication's side effects. Labels already warn of possible psychiatric reactions, but the panel recommended noting that some people have died, the AP reports. Drugmaker Roche says flu alone can trigger problems such as delirium and wants the labels to make that clear as well. More »

      Tags

      FDA  • GlaxoSmithKline  • Tamiflu  • Relenza  • flu medications

    • Diabetes Drug Given Strictest Warning Label

      newser  |  Wall Street Journal  |  Nov 14, 07 3:20 PM CST

      Diabetes Drug Given Strictest Warning Label

      The FDA has applied its harshest warning to the diabetes drug Avandia, declaring the product potentially increases risk of heart attacks. Now marked with a “black box” warning, GlaxoSmithKline’s drug will stay on the market pending a continuing “safety assessment,” the Wall Street Journal reports; FDA officials say the agency remains split on the wisdom of pulling the drug immediately. More »

      Tags

      FDA  • diabetes  • GlaxoSmithKline  • Avandia  • black box  • Actos

  • October 2007

    • Court Blocks New Patent Rules

      newser  |  Wall Street Journal  |  Oct 31, 07 10:40 PM CDT

      Court Blocks New Patent Rules

      A Federal judge has blocked the US Patent and Trademark Office from implementing tough new patent rules with a temporary injunction in a suit brought by GlaxoSmithKline. The Wall Street Journal reports the new rules would have limited the number of times patent holders may make minor changes to existing patent applications, known as continuances, a favorite maneuver of pharma companies. More »

  • July 2007

    • FDA Panel Votes to Keep Avandia on Shelves

      newser  |  Wall Street Journal  |  Jul 30, 07 5:38 PM CDT

      FDA Panel Votes to Keep Avandia on Shelves

      An FDA panel said today that GlaxoSmithKline's diabetes drug Avandia should remain in drugstores, despite earlier evidence the pill ups heart failure risks. Glaxo has defended its drug, countering that the risks associated with the popular Avandia are the same as those of other diabetes drugs. More »

      Tags

      health  • drugs  • FDA  • safety  • diabetes  • GlaxoSmithKline  • Avandia  • heart failure

    • Dow Sinks Further on Credit Jitters

      newser  |  Wall Street Journal  |  Jul 27, 07 4:10 PM CDT

      Dow Sinks Further on Credit Jitters

      Stocks tumbled more than 200 points for the second day in a row, on fears that small-cap securities might be especially hard hit by a possible collapse in certain financial services. The Dow was down 208.10 to 13265.47, despite a report that the GDP grew faster this quarter than it has in a year—but the Russell 2000, which measures small stocks, dipped 1.7% into negative territory for the year. More »

      Tags

      S&P 500  • Nasdaq  • Wall Street  • FDA  • stocks  • GDP  • GlaxoSmithKline  • Avandia

  • June 2007

    • Controversy Rages Over Diabetes Drug's Heart Risks

      newser  |  New York Times  |  Jun 6, 07 12:16 PM CDT

      Controversy Rages Over Diabetes Drug's Heart Risks

      Troubling questions about the diabetes drug Avandia persisted yesterday as an FDA official revealed that she was barred from recommending a critical warning about the medication, the Times reports. In the run-up to congressional hearings that began today, manufacturer GlaxoSmithKline rushed to disseminate interim clinical findings in hopes of blunting the controversy. More »

      Tags

      health  • medicine  • FDA  • diabetes  • heart attack  • heart  • GlaxoSmithKline  • Avandia

  • May 2007

    • Glaxo Stems Stock Slide Over Avandia

      newser  |  Daily Telegraph (UK)  |  May 31, 07 6:44 AM CDT

      Glaxo Stems Stock Slide Over Avandia

      Glaxo shares pulled out of a tailspin after the pharma giant defended its second biggest selling drug, Avandia, against claims that it triggers heart attacks.  A sharply worded letter from the company's chief medical officer on the website of medical journal The Lancet pointed out that the increased incidence of heart attacks among Avandia patients—0.6%—was still very small. More »

      Tags

      drugs  • medicine  • diabetes  • heart attack  • GlaxoSmithKline  • Avandia  • pharma

    • FDA Warned of Avandia Risks Years Ago

      newser  |  New York Times  |  May 24, 07 1:56 PM CDT

      FDA Warned of Avandia Risks Years Ago

      A diabetes doctor warned the FDA of heart risks posed by the diabetes drug Avandia seven years ago, the New York Times reports. The same concerns raised by Dr. John Buse in a 2000 letter were reiterated in a study published by cardiologist Steven Nissen this week. More »

      Tags

      health  • diabetes  • GlaxoSmithKline  • Avandia  • pharma

    • Drug Company Nemesis Strikes Again

      newser  |  Wall Street Journal  |  May 22, 07 1:32 PM CDT

      Drug Company Nemesis Strikes Again

      The doctor who helped to raise concerns about the painkiller Vioxx is back—with the study released earlier this week linking the same company's popular diabetes drug, Avandia, to higher risk of heart attacks. The Wall Street Journal looks at 58-year-old cardiologist Steven Nissen's role in identifying and publicizing drug risks. More »

      Tags

      drugs  • medicine  • FDA  • diabetes  • pharmaceutical companies  • GlaxoSmithKline  • Avandia  • Vioxx

    • Diabetes Drug Ups Heart Risk

      newser  |  Associated Press  |  May 21, 07 3:15 PM CDT

      Diabetes Drug Ups Heart Risk

      A popular diabetes drug may increase heart attack risks, a study reported in the New England Journal of Medicine concludes. Patients who took Avandia, which treats Type 2 diabetes, were 43% more likely to have a heart attack than those who took a placebo, the Cleveland Clinic study found. More »

      Tags

      health  • medicine  • FDA  • medical research  • diabetes  • heart attack  • pharmaceutical companies  • GlaxoSmithKline  • Avandia  • pharma

16 Stories

Today's Most Popular

Loading...

What is Newser?

2008 Codie Finalist

Newser gives you more news in less time. We search for the best and most important stories all over the web, read them for you, and deliver concise and sharp summaries—along with links to the full text. Newser provides a way to stay on top of an ever-expanding horizon of news and opinion—politics, sports, business, trends, technology, personalities, crimes, and controversies. Newser keeps you not just better informed, but, with our signature graphic interface and smart condensed format, more enjoyably informed.

Learn more »